The company also has other options to raise, including selling DSO, a 4th offtake attached with additional cheap funding (i.e non-bank loan as what happened with Ford), government grants/incentives currently already on the table, early JV for the downstream attached with payment. Selling off Buldania I think is not on the cards, unless the payment was fully priced. Many other companies would be happy to have Buldania as their main project. LTR looking to grow and bolt on more projects like Buldania, why would they let it go unless fully priced.
The last time the company spoke on the matter, they said there was no intention to go back to shareholders to raise. Long term shareholders know to take the company at their word. The funding will come, but very unlikely with a cap raise. I recenty sold 10% and could cope with a 1 for 10 cap raise at $2 to raise $440mil, but I doubt all the directors could cope with this. Those directors and independents holding around 20mil shares would need to trump up approx. $4mil not to be diluted in any cap raise. TG would have to trump up over $50mil. They have too much skin in the game, which is a beautifil thing as they are completely aligned with us. There is no rush on a decision about the funding and many options. Whatever they decide will be in our best interests for sure imo.
Certainly all the stars seem to be aligning for LTR. M&A starting, nationalisation of lithium assets OS steering everyone towards Australia, even Toyota realising they need to play catch up and are looking to secure lithium supply.
The big prize for us remains following management to production and a downstream JV, plus any future projects imo. All the activity happening around us just adds to the value of our project. Happy to be a passenger on this train. No reason to get off.
G
- Forums
- ASX - By Stock
- LTR
- Ann: Appointment of Chief Financial Officer
Ann: Appointment of Chief Financial Officer, page-82
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LTR (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.352B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 6273 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.0¢ | 10124 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 6273 | 1.020 |
1 | 375 | 1.015 |
4 | 21488 | 1.000 |
7 | 24787 | 0.980 |
5 | 18628 | 0.975 |
Price($) | Vol. | No. |
---|---|---|
0.950 | 10124 | 2 |
0.965 | 2203 | 3 |
0.970 | 405 | 2 |
0.975 | 50467 | 3 |
0.980 | 44760 | 4 |
Last trade - 09.39am 16/07/2024 (20 minute delay) ? |
Featured News
LTR (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online